Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : ALTA NATURAL HERBS & SUPPLEMENTS LTD. (AHS-ASE) -- Ignore unavailable to you. Want to Upgrade?

To: K. Anders who wrote (5)	9/18/1998 9:41:00 AM
From: KC Jones	Read Replies (1) \| Respond to of 66

HEPATICO TESTS EXPANDED AFTER POSITIVE RESULTS, TSE AND NASD LISTINGS SOUGHT Initial results from HEPATICO give optimism to millions suffering from Hep-C RICHMOND, B.C., Sept. 18 /CNW/ - Company President, Adolph Huckschlag, reports that the Company is beginning to receive preliminary results from the testing of its Hepatitis-C treatment, HEPATICO. ''The test results, which have been reviewed by Dr. David Khoupenia, Alta's Medical Coordinator, are very encouraging'' according to Huckschlag. ''Our results are generally supporting the conclusions of the 17 clinical and pre-clinical trials done in Europe that HEPATICO is effective in normalizing human liver function in Hepatitis-C sufferers.'' said Dr. Khoupenia, ''We have documented substantial declines in liver enzyme counts in as little as 45 days of treatment with HEPATICO. Some participants have seen their Liver Function Test scores return to normal levels within 30 days. In addition, nearly all the patients are reporting decreased fatigue and an increased sense of well being; a sign that liver function is beginning to return to normal.'' Commenting on the timing of the balance of the preliminary data Huckschlag said, ''We expect the majority of our initial results to be in within the next two weeks''. Once Dr. David Khoupenia has had the opportunity to analyze and compare test results the Company will announce their findings along with English-translated copies of the 17 previous trials at a press conference to be announced in early October of this year. Due to overwhelming demand from Hepatitis-C sufferers from around the world Alta's President announced that the Company will immediately expand its HEPATICO tests beyond the current 100 participant limit. Sufferers interested in participating should contact Greg Shafransky at 1.800.535.7502. Participants are required to have full blood workings completed prior to starting the treatment as well as the knowledge and support of their general practitioner. Following up on its commitment to shareholders, Alta has begun the process to list for trading on the Toronto Stock Exchange and the NASDAQ Bulletin Board. The company expects to complete these listings within the next six to nine months. -30- For further information: Investment Information Contact: The Capitalists Capital Corp., @ (800) 969-7222; Product Information Contact: Alta Natural @ (800) 535-7502 ALTA NATURAL HERBS & SUPPLEMENTS LTD. has 13 releases in this database.